2 new studies support benefits of EstroG-100 in the menopause category

2 new studies support benefits of EstroG-100 in the menopause category

Helios CORP and their partner, Sunbio, release two new studies that support the expanded benefits of EstroG-100 in managing some symptoms associated with menopause.

Helios CORP and their partner, Sunbio, completed two new support studies in December 2011, where they showed the expanded benefits of EstroG-100 in managing a broader array of symptoms associated with menopause. Currently EstroG-100 maintains a 12 month Phase I human clinical study, a 4 month, USA based, Phase II human clinical study, 5 toxicity studies, 2 cancer risk studies, 2 liver protective studies, and 2 non-estrogenicity studies.
The first support study evaluated one group of women over the course of 4 weeks, looking at the speed of action within 7 days and 28 days. The group consisted of 20 women consuming 517 mgs of  EstroG-100 over 4 weeks. Within 7 days 50% of the women confirmed significant improvement in multiple symptoms such as Hot Flashes, Vaginal Dryness, Vertigo, Fatigue and Insomnia. 80% of the women showed improvement in these multiple symptoms at 4 weeks of consumption with EstroG-100.
The second study was conducted over a period of 6 weeks with 30 women divided into three groups and consuming 517 mg per day of EstroG-100. GROUP #1: EstroG-100, GROUP#2: A popular facial cosmetic, GROUP#3: Both the EstroG-100 and the cosmetic product. Each group was evaluated for skin wrinkles, moisture, tone and blushing. Average improvement of all four categories was 50% greater than baseline in GROUP #3.
EstroG-100 is one of the safest ingredients in the menopause category, all treatments, and works on multiple symptoms, in a short period of time. Utilizing the binding affinity study as designed by NIH during the 16,000 women study in 2002, EstroG-100 showed no affinity to female receptor sites ER-alpha and ER-beta. NIH indicated in 2002, positive binding affinity suggested links to cancers with ER- alpha/ beta as positive.  Genistein (RE: NIH 2007) and strains of Rhubarb Extract showed ER-beta positive, or binding affinity,  in clinical studies. EstroG-100 also maintains two studies showing liver protective qualities.
About Helios and Sunbio: Helios Corp. and Sunbio are a privately owned and global companies that develop new ideas, science, and cultural remedies that can be translated into commercial applications for the benefit of manufacturers and consumers. Claims and representations are based on the information, data, clinical studies,  and remedies as provided by our science and manufacturing partners.
Hide comments


  • Allowed HTML tags: <em> <strong> <blockquote> <br> <p>

Plain text

  • No HTML tags allowed.
  • Web page addresses and e-mail addresses turn into links automatically.
  • Lines and paragraphs break automatically.